within Pharmacolibrary.Drugs.ATC.L;

model L01AA03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.266666666666666e-06,
    adminDuration  = 600,
    adminMass      = 140 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0482,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0193,
    k12             = 0.206,
    k21             = 0.206
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01AA03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Melphalan is an alkylating agent used in the treatment of multiple myeloma and ovarian cancer. It works by cross-linking DNA, thus inhibiting DNA and RNA synthesis and leading to cell death. It is still approved and in clinical use, particularly for hematological malignancies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from adult patients with multiple myeloma receiving intravenous melphalan for conditioning therapy prior to stem cell transplantation.</p><h4>References</h4><ol><li><p>Barta, SK, et al., &amp; Braunschweig, I (2017). Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. <i>Clinical lymphoma, myeloma &amp; leukemia</i> 17(10) 650–657. DOI:<a href=\"https://doi.org/10.1016/j.clml.2017.06.005\">10.1016/j.clml.2017.06.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28684379/\">https://pubmed.ncbi.nlm.nih.gov/28684379</a></p></li><li><p>Pinguet, F, et al., &amp; Bressolle, F (1997). Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. <i>Anticancer research</i> 17(1B) 605–611. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9066587/\">https://pubmed.ncbi.nlm.nih.gov/9066587</a></p></li><li><p>Koltun, M, et al., &amp; McIntosh, MP (2010). Preclinical comparison of intravenous melphalan pharmacokinetics administered in formulations containing either (SBE)7 m-β-cyclodextrin or a co-solvent system. <i>Biopharmaceutics &amp; drug disposition</i> 31(8-9) 450–454. DOI:<a href=\"https://doi.org/10.1002/bdd.725\">10.1002/bdd.725</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20865695/\">https://pubmed.ncbi.nlm.nih.gov/20865695</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01AA03;
